TIL Instil Bio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789769 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY71.9%
TTM EPS YoY73.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-19.2%
ROA-10.4%
ROIC (approx.)-21.8%
Asset turnover—
Leverage & solvency
Liabilities / assets47.6%
Debt / equity0.00x
Current ratio10.42x
Interest coverage-4.69x
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | $0 |
| R&D expense | $24.74M | $11.84M | $39.60M | $141.06M | $107.25M |
| SG&A expense | $27.22M | $44.21M | $47.55M | $62.23M | $48.31M |
| Operating income | -$78.58M | -$73.54M | -$159.17M | -$226.46M | -$155.56M |
| Interest expense | $5.83M | $8.99M | $5.21M | $1.88M | $0 |
| Pretax income | -$71.37M | -$74.14M | -$156.09M | -$225.25M | -$156.75M |
| Income tax | $0 | — | $0 | -$2.07M | $39,000 |
| Net income | -$71.37M | -$74.14M | -$156.09M | -$223.18M | -$156.79M |
| EBITDA | -$78.05M | -$69.93M | -$154.41M | -$220.47M | -$152.81M |
| EPS (basic) | -10.70 | -11.39 | -24.00 | -34.46 | -1.48 |
| EPS (diluted) | -10.70 | -11.39 | -24.00 | -34.46 | -1.48 |
| Weighted avg. shares (diluted) | 6.67M | 6.51M | 6.50M | 6.48M | 105.99M |
| Balance sheet | |||||
| Cash & equivalents | $6.64M | $10.63M | $10.70M | $43.72M | $38.09M |
| Short-term investments | $69.49M | — | $141.16M | $217.20M | $416.51M |
| Current assets | $192.42M | $124.47M | $160.76M | $269.38M | $464.02M |
| PP&E, net | $126,000 | $129.41M | $138.68M | $196.88M | $122.00M |
| Goodwill | — | — | — | $0 | $5.72M |
| Total assets | $204.51M | $263.57M | $325.63M | $482.13M | $609.98M |
| Current liabilities | $7.03M | $7.90M | $10.56M | $32.79M | $41.36M |
| Total liabilities | $91.84M | $94.13M | $99.80M | $118.52M | $54.78M |
| Shareholders' equity | $112.67M | $168.27M | $225.83M | $363.61M | $555.20M |
| Shares outstanding | 6.78M | 6.53M | 6.50M | 6.50M | 129.03M |
| Cash flow statement | |||||
| Operating cash flow | -$36.62M | -$55.70M | -$82.03M | -$180.16M | -$122.14M |
| Capital expenditure | — | $0 | $20.66M | $84.59M | $57.83M |
| Free cash flow | — | -$55.70M | -$102.69M | -$264.75M | -$179.97M |
| Investing cash flow | $25.48M | $53.97M | $41.13M | $114.54M | -$474.40M |
| Financing cash flow | $7.29M | $1.75M | $8.08M | $71.89M | $393.16M |
| Depreciation & amortization | $534,000 | $3.61M | $4.76M | $5.99M | $2.75M |
| Stock-based compensation | $8.69M | $17.26M | $18.17M | $30.44M | $26.20M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.